CIBC Private Wealth Group LLC raised its stake in Humana Inc (NYSE:HUM) by 0.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 56,554 shares of the insurance provider’s stock after buying an additional 470 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Humana were worth $16,832,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. D.A. Davidson & CO. lifted its position in Humana by 11.4% in the second quarter. D.A. Davidson & CO. now owns 2,974 shares of the insurance provider’s stock valued at $885,000 after buying an additional 305 shares during the last quarter. Victory Capital Management Inc. lifted its position in Humana by 12.0% in the second quarter. Victory Capital Management Inc. now owns 15,382 shares of the insurance provider’s stock valued at $4,578,000 after buying an additional 1,645 shares during the last quarter. First Trust Advisors LP lifted its position in Humana by 49.7% in the second quarter. First Trust Advisors LP now owns 182,290 shares of the insurance provider’s stock valued at $54,255,000 after buying an additional 60,501 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in Humana by 425.8% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 24,975 shares of the insurance provider’s stock valued at $7,433,000 after buying an additional 20,225 shares during the last quarter. Finally, Altman Advisors Inc. acquired a new position in Humana in the second quarter valued at about $2,015,000. 93.78% of the stock is currently owned by institutional investors.

Several analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Humana from a “buy” rating to a “hold” rating in a research report on Wednesday. Citigroup reissued a “buy” rating and set a $340.00 price target (up previously from $280.00) on shares of Humana in a research report on Friday, June 1st. Argus increased their price target on shares of Humana from $270.00 to $330.00 and gave the stock a “buy” rating in a research report on Monday, April 16th. Oppenheimer increased their price target on shares of Humana from $305.00 to $311.00 and gave the stock an “outperform” rating in a research report on Thursday, May 3rd. Finally, Jefferies Financial Group increased their price target on shares of Humana from $356.00 to $372.00 and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Seven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $318.17.

In related news, insider William Kevin Fleming sold 15,637 shares of the firm’s stock in a transaction that occurred on Monday, June 4th. The shares were sold at an average price of $293.08, for a total value of $4,582,891.96. Following the sale, the insider now owns 15,650 shares of the company’s stock, valued at $4,586,702. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Elizabeth D. Bierbower sold 6,036 shares of the firm’s stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $300.91, for a total transaction of $1,816,292.76. Following the completion of the sale, the insider now directly owns 21,683 shares in the company, valued at approximately $6,524,631.53. The disclosure for this sale can be found here. In the last ninety days, insiders sold 104,976 shares of company stock worth $32,165,337. 0.60% of the stock is owned by corporate insiders.

Shares of NYSE:HUM opened at $323.71 on Friday. The company has a market capitalization of $44.33 billion, a P/E ratio of 25.20, a PEG ratio of 1.60 and a beta of 0.93. Humana Inc has a fifty-two week low of $231.90 and a fifty-two week high of $327.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.43.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.79 by $0.17. The firm had revenue of $14.26 billion for the quarter, compared to analysts’ expectations of $14.16 billion. Humana had a net margin of 2.48% and a return on equity of 17.43%. During the same quarter last year, the company earned $3.49 earnings per share. analysts predict that Humana Inc will post 14.18 earnings per share for the current fiscal year.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Recommended Story: Outstanding Shares and The Effect on Share Price

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.